A case risk study of lactic acidosis risk by metformin use in type 2 diabetes mellitus tuberculosis coinfection patients

1. Introduction

Tuberculosis (TB) remains a major cause of morbidity and mortality throughout the world; one-third of the world’s population is estimated to be infected with M. tuberculosis whereby approximately nine million people develop the disease each year, and almost two million die annually as a result. DM–TB coinfection is associated with poor glycemic control in DM patients, and thus elevated proinflammatory state. People with DM had approximately three times the risk of developing TB disease as people without.

Metformin hydrochloride (MET) MET, the biguanide, have been used for treating type 2 diabetes mellitus for more than 60 years. MET works by inhibiting the production of hepatic glucose, reducing intestinal glucose absorption, and improving glucose uptake and utilization. Recently, by a comprehensive in silico study, MET was known to have possibilities of being utilized as a combination drug with existing antibiotics for TB therapy, and by an extensive in vitro study, MET was reported to control the growth of drug-resistant M. tuberculosis.
strains via production of mitochondrial reactive oxygen species and facilitating phagosome-lysosome fusion.\textsuperscript{16,17}

MET is not metabolized by P450 enzymes\textsuperscript{12,13,18}; thus, it has no interaction with rifampicin (RIF) that could decrease the therapy efficacy. However, interaction between MET and RIF increases the expression of organic cation transporter (OCT1) and hepatic uptake of MET, leading to enhanced lowering of glucose levels.\textsuperscript{19,20}

In our previous study, MET was given to type 2 DM newly TB coinfection patients, which improved the superoxide dismutase (SOD) level (unpublished). SOD improvement after MET therapy is predicted to enhance antituberculosis efficacy and is considered to reduce the intracellular growth of \textit{M. tuberculosis}. Collectively, these data indicate that MET is a promising candidate for host-adjunctive therapy for enhancing the effective treatment of TB.\textsuperscript{15,21}

Although MET has several advantages in improving treatment of TB, MET use is still considered to be contraindicated in many chronic conditions that may increase the risk of tissue anoxia, the development of MALA, a fatal metabolic condition, and especially pulmonary diseases due to the existence of potential hypoxia.\textsuperscript{17,22,23}

Lactic acidosis is characterized by an elevated blood lactate concentration (>45.0 mg/dL or >5.0 mmol/L), decreased blood pH (<7.35), and electrolyte disturbances with increased anion gap.\textsuperscript{17,23-30} It also has signs and symptoms of inadequate oxygen (hypoxia) such as shortness of breath, rapid breathing, paleness, sweating, nausea, muscle weakness, abdominal pain, and coma.\textsuperscript{22,26,31}

The objective of this study is to assess the risk of lactic acidosis associated with MET use in patients with type 2 DM newly TB coinfection, as well as combination of MET with golden standard therapies, insulin, and TB treatment regimens. Another objective is to evaluate levels of blood lactate, measured at during treatment.

2. Materials and methods

2.1. Study design

The objective of this study was to identify clinical effect of MET to modulate host immune system and its ability to control the growth of intracellular \textit{M. tuberculosis}. Thus, an observational clinical study was done and carried out at outpatient ward of Surabaya Paru Hospital. Patient’s inclusion criteria were the following: (1) patients with DM with new case of TB coinfection, who were given insulin and TB treatment regimens; (2) positive \textit{M. tuberculosis} in sputum smear; (3) age of 25–60 years; (4) has normal liver function and renal function; (5) not in hypoxia condition, and on presentation, peripheral oxygen saturation level must be higher than 92%.

During this clinical study, type 2 DM newly TB coinfection patients were divided into two groups. First group was MET group, in which the patients were given MET accompanying insulin and TB treatment regimens, the golden standard therapy of DM-TB coinfection. MET therapy was given for at least 2 months. Second group, a comparison group, was non-MET group, in which the patients were given insulin and TB treatment regimens.

We evaluated MET combined with insulin and TB treatment regimens. MET therapy was given for at least 2 months. During MET therapy, as a follow-up program, patients were physical examined weekly; thus, signs and symptoms for lactic acidosis were monitored. Lactate level was measured after 2-month MET therapy for MET group. For comparison, patients belonging to non-MET group, who were given insulin and TB treatment regimens, were also physical examined weekly and lactate level was measured after 2-month insulin and anti-TB therapy.

2.2. Diagnosis and management therapy

The diagnosis of TB was established by (1) clinical symptoms and signs of TB, such as chronic productive cough, unintentional weight loss; (2) positive sputum smear of acid-fast bacteria by microscopic Ziehl–Neelsen-stained sputum slides; and (3) chest radiographs with suggestive features of TB. Diagnosis of DM was established by fasting and 2 h after meal blood glucose levels. HbA1c was measured after 2 months of MET therapy, as evaluation.

Patients diagnosed with TB were registered and treated with TB treatment regimens for a period of 6 months in accordance to WHO guidelines.\textsuperscript{32-34} Management therapy for achieving good glycemic control was insulin therapy.

These following drugs were used: MET (Metformin\textsuperscript{6}), insulin (Humulin\textsuperscript{6}), RIF, isoniazid (INH), pyrazinamide (PYR), and ethambutol (ETH). MET was given 1000–1500 mg in divided daily dose for at least two months or during intensive phase of TB treatment, accompanying insulin therapy and TB treatment regimens.

2.3. Lactate blood measurement

After at least 2 months therapy, whole blood samples, in both groups, were measured by using Bionsen C-line glucose and lactate analyzer\textsuperscript{6} to test lactate blood levels.\textsuperscript{26}

3. Results

3.1. Characteristics of patients

During this study period, there were 476 cases of new TB infection and 156 cases (~30%) of what were type 2 DM newly TB coinfection. 42 patients, with equal number of males and females, were eligible and participated in this observational study (Table 1). The condition in both groups was homogenous (\(p = 0.17; \ p > 0.05\)) using Saphiro Wilk test. The youngest patient’s age was 26 years.

<table>
<thead>
<tr>
<th>Table 1 – Characteristics of patients' sex and ages.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
</tr>
<tr>
<td>------------</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td>Female</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>
Table 2 – Distribution of patient’s eligibility criteria.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>MET group</th>
<th>Non-MET group</th>
<th>p (difference)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c (g/dL)</td>
<td>8.82 ± 1.91</td>
<td>9.52 ± 2.02</td>
<td>0.379</td>
</tr>
<tr>
<td>Oxygen saturation (SpO2) (%)</td>
<td>98.06 ± 0.73</td>
<td>97.47 ± 0.83</td>
<td>0.308</td>
</tr>
<tr>
<td>BUN (mg/dL)</td>
<td>0.95 ± 0.16</td>
<td>0.93 ± 0.13</td>
<td>0.980</td>
</tr>
<tr>
<td>Creatinine serum (U/L)</td>
<td>23.92 ± 11.92</td>
<td>27.3 ± 12.01</td>
<td>0.103</td>
</tr>
<tr>
<td>SGOT (U/L)</td>
<td>17.63 ± 6.16</td>
<td>14.44 ± 6.48</td>
<td>0.354</td>
</tr>
<tr>
<td>SGPT (U/L)</td>
<td>19.22 ± 8.73</td>
<td>16.09 ± 7.56</td>
<td>0.509</td>
</tr>
</tbody>
</table>

Table 3 - Lactate blood level.

<table>
<thead>
<tr>
<th>MET group (mmol/L)</th>
<th>Non-MET group (mmol/L)</th>
<th>p (difference)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.77 ± 0.60</td>
<td>1.71 ± 0.54</td>
<td>0.240</td>
</tr>
</tbody>
</table>

Distribution of patient’s eligibility criteria such as HbA1c, oxygen saturation, renal function (BUN and creatinine serum), and liver function (SGOT, SGPT) are shown in Table 2. All data were normally distributed using Saphiro Wilk test; thus, we continued analysis of the data for the difference using paired T-test statistics with 95% confidence.

Blood glucose condition for both groups was similar (p = 0.26); thus, we dismissed the influence of hyperglycemia condition on lactate blood level.²⁶,³⁵

3.2. Lactate blood level

After observational of MET therapy, on divided daily dose of 1000–1500 mg for at least 2 months accompanying insulin therapy and TB treatment regimens. Lactate blood levels were measured after 2 months of MET therapy.

There was no incidence of lactic acidosis event during this period. Additionally, other side effects of MET therapy such as gastrointestinal intolerance were also reported. Only two cases of mild gastrointestinal disturbance, such as mild frequent diarrhea and nausea/vomiting, were reported.

Lactate blood level in both groups was normally distributed using Saphiro Wilk test (p = 0.24; p > 0.05); then, we analyzed the difference between both groups using paired T-test (Table 3 and Fig. 1).

Comparing MET group with non-MET group, we concluded there was no statistically significant difference of lactate blood level after at least 2 months of MET therapy (p > 0.05). The level of blood lactate was in the normal range (less than 2.50 mmol/L) both in MET group and also non-MET group.

4. Discussion

The optimum treatment strategy for DM-TB coinfection remained unclear to date. Uncontrollable chronic hyperglycemia in DM patients increases the incidence of TB therapy failure. Besides, DM is also associated with deaths due to TB infection and relapse of TB infection.⁴,⁹,³⁶–³⁸ TB treatment for TB patients with DM is no different from treatment for patients without DM.⁵ Insulin becomes the main therapy to control hyperglycemia condition. In this study, DM-TB patients got insulin and TB treatment, with TB regimen dose referring to World Health Organization (WHO).

Identification of new host-directed therapies that can improve clinical outcomes for DM-TB coinfection patients has been a priority by the WHO, leading to the study of immunomodulatory agents for adjunct treatment of TB.²¹,³⁹–⁴¹

MET in some studies enhances M. tuberculosis – specific host immunity, reduces inflammation, and enhances efficacy of TB treatment. MET, which is not metabolized by P450, does not decrease the efficacy of RIF. Interaction between MET and RIF increases OCT1 expression, which has its role in blocking M. tuberculosis transcription. SOD is one essential factor to prevent INH resistency, and MET has been known to increase SOD.⁴⁴–⁴⁶ Hence, it can be concluded that MET possesses the potency to prevent INH resistency. MET treatment was associated with improved control of M. tuberculosis infection and decreased disease severity.⁴,¹⁵

The use of MET may cause side effects such as digestion problem (anorexia, nausea, vomit, and diarrhea), lactate level increase, vitamin B₁₂ malabsorption, and kidney/heart function problem.¹²,¹³ Though the incidence of MET-associated lactic acidosis (MALA) is low, it must be prevented as it threatens lives. In this study, MALA can occur in very rare situations such as (1) drug-induced hepatitis caused by OAT and/or MET and (2) lung damage, which becomes worse causing hypoxia.⁴⁷,⁴⁸ MALA prevention in this study has been determined at the following precondition criteria: (1) minimal to moderate lung lesion; (2) oxygen saturation > 92%; (3) normal function of SGOT and SGPT, and normal kidney function (BUN and SK) (see Table 2). This study also provides consultation,
information, and education related to symptoms of lactic acidosis.

Lactic acidosis is also influenced by high glycemic index. To minimize the bias due to hyperglycemia, HbA1c measurement was done 2 months after the MET therapy accompanying insulin and TB treatment regimens for MET group. HbA1c, for non-MET group, was also performed after 2 months of insulin and OAT therapy, or after intensive TB therapy phase was done (see Table 2).

There were no MALA cases during this 2-month study, both for MET and non-MET groups. It was even proved that blood lactate level was in normal range (<2.50 mmol/L). The blend of MET, insulin, and TB treatment was relatively safe for DM–TB patients if some condition was controlled (see Table 3).

In this study, we also found that the participants (<5%) in MET group experienced mild gastrointestinal intolerance (nausea and vomit). This can be related to high concentrated MET or glucose metabolism change causing local irritation, fluid retention, and salt malabsorption, leading to loose stools and diarrhea.

In this study, we were not yet involved TB patients non-type 2 DM, even in our knowledges MET, which has low hypoglycemic effect, could be beneficial in TB patients non-DM due to anti-inflammatory effect and increasing efficacy of TB treatment.21,41 In future, after establishing MET clinical effect in type 2 DM–TB coinfection, we may combine MET therapy with anti-TB for TB patients with non-type 2 DM in order to evaluate the efficacy of MET therapy in immune modulation.

5. Conclusion

Lactic acidosis in MET therapy is a rare but important adverse event and clearly we need to prevent it. In this case risk study, there is no evidence of MALA. Elevation of levels of lactate, compared with placebo, also did not occur. Thus, we concluded that MET use in type 2 DM–TB coinfection did not induce lactic acidosis. Furthermore, this result, due to our limitation in number of participants involved in the study, needs to be confirmed in a cohort study.

Conflicts of interest

The authors have none to declare.

Acknowledgement

The authors thank almighty God for helping them complete this work successfully. They thank Sri Hariastuti and team (Clinical Pathology, Diagnostic Center Dr. Soetomo Hospital, Surabaya, Indonesia) for their technical assistance.

They thank Prof. Dr. Jusak, Dr., M.S., and Sp.PK(K) for helping with the discussion part. This study was supported in part by grant-in-aid for Ph.D. research from Lembaga Pengelola Dana Pendidikan (LPDP), the Ministry of Economic and the Ministry Education, Research and Technology of Republic of Indonesia.

REFERENCES
